ATP13A2 and neuronal ceroid lipofuscinosis: Following KRS, ATP13A2 was determined to be mutated in forms of neuronal ceroid lipofuscinosis (NCL), hereditary spastic paraplegia (HSP), and most recently amyotrophic lateral sclerosis (ALS) (2–7).